CoreValve implantation for severe aortic regurgitation: a multicentre registry

Luca Testa, Azeem Latib, Marco L uciano Rossi, Federico De Marco, Marco De Carlo, Claudia Fiorina, Jacopo Oreglia, Anna S onia Petronio, Federica Ettori, Stefano De Servi, Silvio Klugmann, Gian P aolo Ussia, Corrado Tamburino, Paolo Panisi, Nedy Brambilla, Antonio Colombo, Patrizia Presbitero, Francesco Bedogni

Research output: Contribution to journalArticlepeer-review


AIMS: We sought to evaluate the outcome of transcatheter aortic valve replacement (TAVR) with the CoreValve Revalving System (CRS-TAVR) in inoperable patients presenting with severe aortic regurgitation (AR), compared to in patients treated for severe native aortic stenosis (AS). From October 2008 to January 2013, 1,557 consecutive patients undergoing CRS-TAVR, of whom 26 (1.6%) presented with AR, were prospectively followed. Compared with patients with AS, patients with AR were significantly younger (mean age 73±10 vs. 82±6, p=0.02), more frequently in NYHA Class III/IV (95% vs. 73%, p=0.01) and had a higher incidence of severe pulmonary hypertension (sPAP >60 mmHg, 31% vs. 10%, p=0.007). Log EuroSCORE and STS score were similar. VARC-2-defined device success was lower in the AR group (79% vs. 96%, p=0.006). At one month, patients treated for AR had a higher overall mortality (23% vs. 5.9%; OR 4.22 [3.03-8.28], p

Original languageEnglish
Pages (from-to)739-745
Number of pages7
Issue number6
Publication statusPublished - Oct 1 2014

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'CoreValve implantation for severe aortic regurgitation: a multicentre registry'. Together they form a unique fingerprint.

Cite this